WeVote
Log In

Bill

Bill

SD 2652

340B/High-Cost Drugs Impact Report

194th Legislature (2025-2026)

Massachusetts directs health department to study federal 340B drug pricing program's effects on state healthcare costs and medication accessibility.

Placed on file
0
WeVote Research Nonpartisan
Bill Summary · SD 2652

Legislative bill overview

SD 2652 requires the Massachusetts Department of Public Health to study and report on the impact of the federal 340B drug pricing program on state healthcare costs and drug accessibility. The bill mandates an examination of how this program—which allows eligible hospitals and clinics to purchase certain drugs at discounted prices—affects pricing, patient access, and the state's pharmaceutical expenditures.

Why is this important

The 340B program is a significant but often opaque component of pharmaceutical pricing that affects state Medicaid budgets, insurance premiums, and drug availability. Massachusetts spends billions annually on prescription drugs, and understanding how this federal program influences those costs could inform future healthcare policy decisions and budget planning. The report could reveal whether the program is achieving its intended goals of expanding access or whether adjustments are needed.

Potential points of contention

  • Definitional scope: Uncertainty about what constitutes "impact"—whether the report examines only direct savings, indirect effects on pricing, or broader market effects
  • Program defense vs. reform: Stakeholders disagree on whether 340B needs scrutiny (some argue it's working as intended; others see it as allowing drug manufacturer profiteering)
  • Resource allocation: Questions about report costs and whether Massachusetts should conduct its own analysis versus relying on existing federal data and GAO studies

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.